ArticleACS pharmacology & translational science2025
Discovery of Anticancer Indole-Based 4,5-Dihydroisoxazole Derivative with Selectivity toward Leukemia Cells.
Article in ACS pharmacology & translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A novel dihydroisoxazole derivative DHI9 suppresses colorectal cancer cell survival by inducing oxidative stress, DNA damage, and mitochondrial apoptosis while targeting Akt and Wnt/β-catenin signalling.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Emerging Indole and Azaindole Hybrid Agents for Leukemia Therapy: Recent Research Advances and Therapeutic Potential.Archiv der Pharmazie · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Isoxazole-derived compounds possess various bioactivities including anticancer, immunomodulatory, antimicrobial, anti-inflammatory, or antipsychotic effects with successful implementation in clinical practice. Treatment of hematological malignancies with isoxazole derivatives represents a promising area of research. The present study aimed to synthesize 11 novel 3,5-diaryl-4,5-dihydroisoxazole compounds and assess their antiproliferative effects using cell viability assay in a panel of nine cancer types including breast (MCF-7), colon (HCT-116), cervical (HeLa), lung (A549), ovarian cancer (A2780), glioblastoma (U87), hepatocellular carcinoma (HepG2), and leukemia (Jurkat and HL-60) cells as well as two noncancerous cell lines (Bj-5ta and MCF-10A). The most promising compound was further screened using flow cytometry, Western blot, fluorescence microscopy, and chemotaxis/migration cell assays. Compound (±)-3-[3-(4-bromophenyl)-4,5-dihydro-1,2-oxazol-5-yl]-1-methyl-1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.